OBJECTIVE: To assess factors associated with insulin regimens at initiation, changes in treatment and metabolic control over 2 years of insulin therapy in patients with type 2 diabetes in five countries. RESEARCH DESIGN AND METHODS: TREAT was a prospective, 24 month, observational study in patients with type 2 diabetes initiating insulin in clinical practice. Patient characteristics were collected at baseline and metabolic outcomes at 3, 6, 12, 18 and 24 months after initiation. RESULTS: A total of 985 patients were enrolled, 886 assessed at baseline and 734 (82.8%) at 24 months. Baseline characteristics varied between countries: 52.8% of patients were men; mean age was 60.4 years; body mass index, 29.7 kg/m²; time since diagnosis, 10.1 years; HbA1c, 9.6%. Less than 25% of patients met ADA/IDF targets for blood pressure/LDL cholesterol. Overall, 50.1% of patients were initiated on long/intermediate insulin, 39.3% on mixture and 7.8% on basal-bolus; distribution varied between countries. Patients on long/intermediate were more likely to have lower baseline HbA1c and be intensified to other regimens (19.4%). No oral antidiabetic medication was used for 16.4% initiating on long/intermediate, 47.4% on mixture and 62.3% with basal-bolus. Overall, mean HbA1c decreased from 9.6% to 7.6%, with little difference between regimens at endpoint. The percentage of patients with hypoglycaemia was highest at 6 months and with basal-bolus. LIMITATIONS: Sites were not selected at random. Drop-out of patients prior to 24 months may have introduced a bias that favoured responders. CONCLUSIONS: Mean baseline HbA1c was high, indicating delayed initiation of insulin treatment. Blood pressure and lipids were suboptimally controlled. Insulin regimens varied between countries, changed little and resulted in similar HbA1c levels after 24 months.
OBJECTIVE: To assess factors associated with insulin regimens at initiation, changes in treatment and metabolic control over 2 years of insulin therapy in patients with type 2 diabetes in five countries. RESEARCH DESIGN AND METHODS: TREAT was a prospective, 24 month, observational study in patients with type 2 diabetes initiating insulin in clinical practice. Patient characteristics were collected at baseline and metabolic outcomes at 3, 6, 12, 18 and 24 months after initiation. RESULTS: A total of 985 patients were enrolled, 886 assessed at baseline and 734 (82.8%) at 24 months. Baseline characteristics varied between countries: 52.8% of patients were men; mean age was 60.4 years; body mass index, 29.7 kg/m²; time since diagnosis, 10.1 years; HbA1c, 9.6%. Less than 25% of patients met ADA/IDF targets for blood pressure/LDL cholesterol. Overall, 50.1% of patients were initiated on long/intermediate insulin, 39.3% on mixture and 7.8% on basal-bolus; distribution varied between countries. Patients on long/intermediate were more likely to have lower baseline HbA1c and be intensified to other regimens (19.4%). No oral antidiabetic medication was used for 16.4% initiating on long/intermediate, 47.4% on mixture and 62.3% with basal-bolus. Overall, mean HbA1c decreased from 9.6% to 7.6%, with little difference between regimens at endpoint. The percentage of patients with hypoglycaemia was highest at 6 months and with basal-bolus. LIMITATIONS: Sites were not selected at random. Drop-out of patients prior to 24 months may have introduced a bias that favoured responders. CONCLUSIONS: Mean baseline HbA1c was high, indicating delayed initiation of insulin treatment. Blood pressure and lipids were suboptimally controlled. Insulin regimens varied between countries, changed little and resulted in similar HbA1c levels after 24 months.
Authors: Haya Ascher-Svanum; Anthony Zagar; Dingfeng Jiang; Dara Schuster; Henry Schmitt; Ellen B Dennehy; David M Kendall; Joel Raskin; Robert J Heine Journal: Diabetes Ther Date: 2015-07-10 Impact factor: 2.945
Authors: Heather Stuckey; Lawrence Fisher; William H Polonsky; Danielle Hessler; Frank J Snoek; Tricia S Tang; Norbert Hermanns; Xavier Mundet-Tuduri; Maria Elizabeth Rossi da Silva; Jackie Sturt; Kentaro Okazaki; Dachuang Cao; Irene Hadjiyianni; Jasmina I Ivanova; Urvi Desai; Magaly Perez-Nieves Journal: BMJ Open Diabetes Res Care Date: 2019-12-11
Authors: Fahri Bayram; Alper Sonmez; Cem Haymana; Tevfik Sabuncu; Oguzhan Sitki Dizdar; Eren Gurkan; Ayse Kargili Carlioglu; Kemal Agbaht; Didem Ozdemir; Ibrahim Demirci; Cem Barcin; Serpil Salman; Tamer Tetiker; Mustafa Kemal Balci; Nur Kebapci; Canan Ersoy; Volkan Yumuk; Peter P Toth; Ilhan Satman Journal: Lipids Health Dis Date: 2020-11-11 Impact factor: 3.876
Authors: Anne Peters; Nathan Cohen; Peter Calhoun; Katrina J Ruedy; Roy W Beck; Thomas W Martens; Shichun Bao; Nelly M Njeru; Stayce E Beck; David A Price Journal: Diabetes Obes Metab Date: 2020-11-17 Impact factor: 6.577